SCHEMBL20529758

SCHEMBL20529758

CCCCC/C=C/NCC(=O)O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 6/20 0.55
PPARD Q03181 5/20 0.55
PPARA Q07869 5/20 0.55
TERT O14746 3/20 0.55
PTPN1 P18031 3/20 0.55
MAPT P10636 3/20 0.55
BLM P54132 3/20 0.55
HSD17B10 Q99714 3/20 0.55
FABP4 P15090 3/20 0.55
TOP1 P11387 3/20 0.55
USP2 O75604 2/20 0.55
LMNA P02545 2/20 0.55
ALOX15 P16050 2/20 0.55
RECQL P46063 2/20 0.55
F7 P08709 2/20 0.55
CYP19A1 P11511 2/20 0.55
F3 P13726 2/20 0.55
PTGS1 P23219 2/20 0.55
NR4A2 P43354 2/20 0.55
KMT2A Q03164 2/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7647197 1.00 PPARG (0.55) PPARGPPARDPPARATERTPTPN1
SCHEMBL5598319 0.98 TERT (0.58) PPARGPPARDPPARATERTPTPN1
SCHEMBL7575667 0.98 TERT (0.58) PPARGPPARDPPARATERTPTPN1
SCHEMBL20529764 0.98 TERT (0.58) PPARGPPARDPPARATERTPTPN1
SCHEMBL7575671 0.98 TERT (0.58) PPARGPPARDPPARATERTPTPN1
SCHEMBL18640772 0.98 TERT (0.58) PPARGPPARDPPARATERTPTPN1
SCHEMBL20529741 0.96 F7 (0.55) PPARGPPARDPPARATERTPTPN1
SCHEMBL20529739 0.96 F7 (0.55) PPARGPPARDPPARATERTPTPN1
SCHEMBL12501477 0.88 ALDH1A1 (0.41) PPARGPPARDPPARATERTPTPN1
SCHEMBL12501476 0.88 ALDH1A1 (0.41) PPARGPPARDPPARATERTPTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210324029-A1 STABLE MODULATORS OF GAMMA-C-CYTOKINE ACTIVITY Bioniz Therapeutics, Inc. 2021-10-21 US claimed
EP-3606940-A1 STABLE MODULATORS OF GAMMA-C-CYTOKINE ACTIVITY Bioniz, LLC (US) 2020-02-12 EP claimed
WO-2018187499-A1 STABLE MODULATORS OF GAMMA-C-CYTOKINE ACTIVITY BIONIZ, LLC (US) 2018-10-11 WO claimed
US-12600757-B2 Peptides inhibiting gamma-c-cytokine activity and methods of use Bioniz Therapeutics, Inc. (US) 2026-04-14 US disclosed
US-20210324029-A1 STABLE MODULATORS OF GAMMA-C-CYTOKINE ACTIVITY Bioniz Therapeutics, Inc. 2021-10-21 US disclosed
EP-3606940-A1 STABLE MODULATORS OF GAMMA-C-CYTOKINE ACTIVITY Bioniz, LLC (US) 2020-02-12 EP disclosed
WO-2018187499-A1 STABLE MODULATORS OF GAMMA-C-CYTOKINE ACTIVITY BIONIZ, LLC (US) 2018-10-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12600757-B2 Peptides inhibiting gamma-c-cytokine activity and methods of use IL15, IL2, IL15RA PPARG 998/4885PPARD 2442/4885PPARA 2161/4885
US-20210324029-A1 STABLE MODULATORS OF GAMMA-C-CYTOKINE ACTIVITY IL2, IL2RA, GMFG PPARG 1025/4885PPARD 3011/4885PPARA 2300/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.